News

INGELHEIM, Germany and SOUTH SAN FRANCISCO, Calif., USA, 9 January 2023 – Boehringer Ingelheim and 3T Biosciences, today announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class…

Current president and CEO of Intellia Therapeutics and previous global head of Abbvie’s R&D brings more than 30 years’ experience leading discovery, development, and launch of groundbreaking blockbuster medicines SAN FRANCISCO, Calif., Oct. 25, 2022 /PRNewswire/ — 3T Biosciences (“3T”), an immunotherapy company changing the future of treatment for solid tumors…

Immunotherapy company developing next-generation, transformative therapies for the treatment of solid tumors and other immune-mediated diseases in broad patient populations Company secured exclusive license with Stanford University for novel TCR-mimetic discovery platform and development stage MAGE-A3 TCRs Stefan Scherer, M.D., Ph.D., named president and CEO, and Christopher DeRespino, MBA, appointed…